Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 19 studies | 30% ± 12% | |
microglial cell | 7 studies | 27% ± 7% | |
astrocyte | 7 studies | 27% ± 10% | |
GABAergic neuron | 7 studies | 32% ± 18% | |
epithelial cell | 6 studies | 24% ± 8% | |
capillary endothelial cell | 6 studies | 22% ± 4% | |
oligodendrocyte | 6 studies | 25% ± 6% | |
vein endothelial cell | 5 studies | 19% ± 1% | |
retinal cone cell | 5 studies | 28% ± 12% | |
retina horizontal cell | 4 studies | 22% ± 9% | |
cardiac muscle cell | 4 studies | 25% ± 2% | |
glutamatergic neuron | 4 studies | 49% ± 18% | |
oligodendrocyte precursor cell | 4 studies | 32% ± 9% | |
interneuron | 4 studies | 39% ± 21% | |
classical monocyte | 3 studies | 17% ± 1% | |
smooth muscle cell | 3 studies | 19% ± 3% | |
retinal rod cell | 3 studies | 26% ± 9% | |
abnormal cell | 3 studies | 23% ± 7% | |
macrophage | 3 studies | 20% ± 5% | |
pericyte | 3 studies | 17% ± 2% | |
neuron | 3 studies | 32% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4357.29 | 1443 / 1445 | 100% | 11.25 | 183 / 183 |
ovary | 100% | 4411.98 | 180 / 180 | 99% | 8.48 | 424 / 430 |
stomach | 99% | 2724.82 | 356 / 359 | 98% | 9.11 | 280 / 286 |
brain | 100% | 4607.90 | 2642 / 2642 | 96% | 4.50 | 676 / 705 |
intestine | 100% | 4802.00 | 966 / 966 | 95% | 5.65 | 502 / 527 |
skin | 100% | 5350.73 | 1808 / 1809 | 94% | 6.28 | 446 / 472 |
lung | 98% | 2550.45 | 569 / 578 | 94% | 4.32 | 1091 / 1155 |
pancreas | 99% | 3188.56 | 326 / 328 | 91% | 2.60 | 162 / 178 |
kidney | 100% | 3703.46 | 89 / 89 | 89% | 4.81 | 802 / 901 |
liver | 100% | 3661.53 | 226 / 226 | 84% | 3.52 | 341 / 406 |
breast | 100% | 5915.87 | 459 / 459 | 84% | 2.39 | 937 / 1118 |
bladder | 100% | 4305.81 | 21 / 21 | 81% | 2.79 | 409 / 504 |
prostate | 100% | 3054.67 | 244 / 245 | 80% | 2.00 | 403 / 502 |
uterus | 100% | 4400.03 | 170 / 170 | 78% | 2.54 | 360 / 459 |
thymus | 100% | 3112.40 | 651 / 653 | 74% | 1.79 | 448 / 605 |
adrenal gland | 100% | 4675.86 | 258 / 258 | 73% | 2.31 | 167 / 230 |
adipose | 100% | 6935.83 | 1204 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 41508.39 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3253.66 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.04 | 1 / 1 |
blood vessel | 100% | 4967.96 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 5610.23 | 853 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 90% | 4472.76 | 832 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 80% | 2.63 | 36 / 45 |
eye | 0% | 0 | 0 / 0 | 75% | 2.22 | 60 / 80 |
lymph node | 0% | 0 | 0 / 0 | 59% | 1.48 | 17 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0018401 | Biological process | peptidyl-proline hydroxylation to 4-hydroxy-L-proline |
GO_0060347 | Biological process | heart trabecula formation |
GO_0051344 | Biological process | negative regulation of cyclic-nucleotide phosphodiesterase activity |
GO_0140252 | Biological process | regulation protein catabolic process at postsynapse |
GO_0043433 | Biological process | negative regulation of DNA-binding transcription factor activity |
GO_0045765 | Biological process | regulation of angiogenesis |
GO_0055008 | Biological process | cardiac muscle tissue morphogenesis |
GO_0060711 | Biological process | labyrinthine layer development |
GO_0006879 | Biological process | intracellular iron ion homeostasis |
GO_0001666 | Biological process | response to hypoxia |
GO_0060412 | Biological process | ventricular septum morphogenesis |
GO_0071731 | Biological process | response to nitric oxide |
GO_0032364 | Biological process | intracellular oxygen homeostasis |
GO_0099159 | Biological process | regulation of modification of postsynaptic structure |
GO_0071456 | Biological process | cellular response to hypoxia |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0098978 | Cellular component | glutamatergic synapse |
GO_0005829 | Cellular component | cytosol |
GO_0014069 | Cellular component | postsynaptic density |
GO_0005737 | Cellular component | cytoplasm |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0031418 | Molecular function | L-ascorbic acid binding |
GO_0160082 | Molecular function | hypoxia-inducible factor-proline dioxygenase activity |
GO_0016706 | Molecular function | 2-oxoglutarate-dependent dioxygenase activity |
GO_0008198 | Molecular function | ferrous iron binding |
GO_0031543 | Molecular function | peptidyl-proline dioxygenase activity |
GO_0005515 | Molecular function | protein binding |
GO_0031545 | Molecular function | peptidyl-proline 4-dioxygenase activity |
Gene name | EGLN1 |
Protein name | Egl-9 family hypoxia inducible factor 1 Egl nine homolog 1 (EC 1.14.11.29) (Hypoxia-inducible factor prolyl hydroxylase 2) (HIF-PH2) (HIF-prolyl hydroxylase 2) (HPH-2) (Prolyl hydroxylase domain-containing protein 2) (PHD2) (SM-20) hypoxia-inducible factor-proline dioxygenase (EC 1.14.11.29) |
Synonyms | C1orf12 PNAS-118 hCG_1810777 PNAS-137 |
Description | FUNCTION: Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF1B. Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes. EGLN1 is the most important isozyme under normoxia and, through regulating the stability of HIF1, involved in various hypoxia-influenced processes such as angiogenesis in retinal and cardiac functionality. Target proteins are preferentially recognized via a LXXLAP motif. . |
Accessions | R4S1C5 R4SCQ0 A0A590UJ78 R4SCC4 A6XP74 ENST00000667629.1 A0A590UJT7 ENST00000366641.4 [Q9GZT9-1] ENST00000670301.1 A0A590UJZ0 ENST00000658954.1 A0A590UJD6 R4RYZ7 R4SCF3 Q9GZT9 I6QYW0 ENST00000654803.1 R4RZ18 R4SCP5 R4RYY7 |